Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...
The decision to divest Opella is part of Sanofi’s ongoing strategy to become a pureplay biopharma company. Opella employs more than 11,000 people worldwide and is known for making Doliprane ...
Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...
GlobalData on MSN4d
Sanofi moves closer to selling controlling stake in $17bn-valued OpellaSanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.
2% stake in Opella, with Sanofi remaining a significant shareholder ... We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people ...
2% stake in Opella, with Sanofi remaining ... approvals from the competent authorities. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback